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Aims The presence of endothelial cell (EC)-derived surface molecules in the circulation is among hallmarks of endothelial
activation and damage in vivo. Previous investigations suggest that upregulation of T-cadherin (T-cad) on the surface of
ECs may be a characteristic marker of EC activation and stress. We investigated whether T-cad might also be shed
from ECs and in amounts reflecting the extent of activation or damage.
Methods
and results
Immunoblotting showed the presence of T-cad protein in the culture medium from normal proliferating ECs and
higher levels in the medium from stressed/apoptotic ECs. Release of T-cad into the circulation occurs in vivo and
in association with endothelial dysfunction. Sandwich ELISA revealed negligible T-cad protein in the plasma of
healthy volunteers (0.90+0.90 ng/mL, n ¼ 30), and increased levels in the plasma from patients with non-significant
atherosclerosis (9.23+ 2.61 ng/mL, n ¼ 63) and patients with chronic coronary artery disease (6.93+1.31 ng/mL,
n ¼ 162). In both patient groups there was a significant (P ¼ 0.043) dependency of T-cad and degree of endothelial
dysfunction as measured by reactive hyperaemia peripheral tonometry. Flow cytometry analysis showed that the
major fraction of T-cad was released into the EC culture medium and the plasma as a surface component of EC-
derived annexin V- and CD144/CD31-positive microparticles (MPs). Gain-of-function and loss-of-function studies
demonstrate that MP-bound T-cad induced Akt phosphorylation and activated angiogenic behaviour in target ECs
via homophilic-based interactions.
Conclusion Our findings reveal a novel mechanism of T-cad-dependent signalling in the vascular endothelium. We identify T-cad
as an endothelial MP antigen in vivo and demonstrate that its level in plasma is increased in early atherosclerosis and
correlates with endothelial dysfunction.
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Introduction
Atherosclerosis is a chronic inflammatory disease of large arteries
that is initiated by activation and injury of the vascular endothelium
upon exposure to multiple cardiovascular risk factors. There is
mounting interest in detecting and influencing both the develop-
ment of atherosclerosis at its non-significant stages and the shift
from ‘indolent disease’ to acute disease. Studies have demon-
strated that endothelial activation and dysfunction detected by
measuring changes in endothelium-dependent vasodilatation or
by analysing plasma levels of soluble inflammatory markers (e.g.
high-sensitivity C-reactive protein, CD40L) can be a prognostic
tool predicting future coronary events.1–4
Among the hallmarks of endothelial activation and damage is the
presence of endothelial cell (EC)-derived surface molecules in the
circulation. Plasma levels of soluble forms of endothelial membrane
proteins (e.g. VCAM-1, E-selectin and P-selectin, LOX-1 receptor)
have variously been shown to reflect the severity and the stage of
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the disease.5 EC membrane proteins (e.g. E-selectin, ICAM-1,
VE-cadherin) are also present in the circulation on microparticles
(MPs), defined as vesicles ,1 mm in size shed from the plasma
membrane by exocytotic budding in response to cell activation,
injury, or apoptosis.6–8 Cellular origin (ECs, leucocytes, lympho-
cytes, erythrocytes, and platelets), amount, and protein compo-
sition of MPs in the circulation have been suggested to be useful
clinical markers for a great variety of diseases with vascular invol-
vement and hypercoagulability.6–8 In addition to their biological
actions in inflammation, immune responses and coagulation MPs
are capable of directly stimulating intracellular signalling and elicit-
ing cellular responses, such as proliferation, survival, adhesion, che-
motaxis, and intercellular communication.7,8
Accumulating evidence supports a role for cell surface
T-cadherin (T-cad) survival responses of vascular cells to activation
and injury of the vasculature.9,10 T-cad expression is increased
in vivo in atherosclerotic lesions from human aorta,11 in experimen-
tal restenotic lesions of the carotid artery,12 and in proliferating
ECs and smooth muscle cells in vitro.13 Upregulation of T-cad in
ECs also occurs during oxidative and endoplasmic reticulum
stress and functions to diminish stress-induced apoptosis.14,15
Overexpression and ligation of T-cad on the EC surface activate
signalling pathways (PI3-kinase, Akt, GSK3b) important for cell
survival, proliferation and angiogenesis.9,14,16
The foregoing studies utilized artificial ligands (i.e. antibodies or
recombinant protein) to induce T-cad ligation. The present study
examines (i) whether T-cad might also be shed from ECs under
conditions of stress and in what form, (ii) whether the shed
T-cad might be a functionally relevant and naturally occurring
ligand for cell surface-expressed T-cad, and (iii) whether T-cad




Established protocols were used for culture of EC, viral transduction,
Western blotting, MP isolation, flow cytometry, electron microscopy,
sandwich ELISA, and angiogenesis in vitro (see Supplementary material
online).
Clinical study
The study complies with the Declaration of Helsinki and was
approved by the regional ethical committee. Informed consent
was obtained from all subjects. They include 225 consecutive
patients who underwent coronary angiography at the Luzerner
Kantonsspital and a group of 30 volunteers younger than
35 years and without any cardiovascular risk factors. Intravascular
ultrasound (IVUS) and quantification of IVUS in the patients was
carried out using Volcano equipment.17 Based on important differ-
ences in clinical and angiographic presentation, patients were
divided into two groups of those with chronic coronary artery
disease (CAD) (n ¼ 163) or with non-significant atherosclerosis
(n ¼ 63). Definition of chronic CAD was angiographically and
IVUS-proven relevant coronary stenosis (lesions greater than
50%) of at least one vessel and with either angina and/or ST
depression during exercise. Definition of non-significant athero-
sclerosis was diffuse luminal irregularities without relevant lesions
(lesions less than 50%) as determined angiographically and by
IVUS. The indication for exam in these patients was symptoms
of angina or dyspnoea or in the course of investigation of arrhyth-
mias or palpitations. In the group of patients with chronic CAD,
mean grade of stenosis was 66.7+ 26.1%, mean plaque burden
was 48.6+ 10.5%, and mean necrotic core volume (% of plaque
volume) was 17.2+8.7%. In the group of patients with non-
significant atherosclerosis, mean grade of stenosis was 6.1+
15.2%, mean plaque burden was 31.6+ 12.4%, and mean necrotic
core volume (% of plaque volume) was 9.5+ 8.1%; all P, 0.001 in
comparison with the group of patients with chronic CAD.
Measurements of reactive hyperaemia-peripheral arterial tono-
metry (RH-PAT) and of T-cad in plasma were performed following
protocols detailed in Supplementary material online.
Statistical analysis
For in vitro studies, differences were variously determined with
one-way or two-way repeated-measures analysis of variance
(ANOVA) with Tukey’s or Bonferroni’s multiple comparison test,
respectively, using Prism 5.0 software (GraphPad Software, San
Diego, CA, USA), or three-way repeated-measures ANOVA with
Bonferroni’s multiple comparison test using STATA Version 9.2
(STATA Corporation, College Station, TX, USA). Statistical analysis
of data from patients and healthy volunteers was performed using
STATA Version 9.2. Continuous variables were compared using
Student’s t-test assuming normal distributions or the Wilcoxon
rank sum test for variables with non-normal distributions. Dichot-
omous variables were compared using the x2-test or Fisher’s exact
test when cell counts were ,5. In patients, Spearman’s correlation
using continuous variables and logistic regression models using
dichotomous variables were used to detect associations between
T-cad plasma levels and the degree of ED as assessed by
RH-PAT. For the purpose of logistic regression analysis, RH-PAT
index was dichotomized at a value of 2.0 and T-cad values were
dichotomized at a detection limit of 1 ng/mL. A significance level
of 0.05 was assumed for all tests.
Results
T-cadherin can be detected in culture
supernatants from endothelial cells
To determine whether T-cad protein is released from EC, con-
ditioned media were harvested from monolayer cultures of par-
ental human umbilical vein endothelial cells (HUVECs) and
HUVEC transduced with native T-cad protein or
T-cad-c-myc-tagged protein following a 24 h culture period. Immu-
noblotting demonstrated the presence of T-cad protein in media
(Figure 1A). Different agents inducing endothelial stress/apoptosis
(TNF-a, hydrogen peroxide, and thapsigargin) increased the
content of T-cad in the medium (Figure 1B). Release of T-cad
into the medium was not prevented by inclusion of various com-
pounds that can inhibit the catalytic cleavage of membrane
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proteins from the cell surface, including protein kinase inhibitors—
bisindoylmaleimide, staurosporine, and phorbol myristate
acetate; protease inhibitors—phenylmethylsulphonyl fluoride,
Sigma proteolytic cocktail, and aprotinin; divalent cation scavenger
ethylenediammine tetraacetic acid; lipid-raft disrupting agent
filipin; phospholipase D metalloproteinase inhibitor 1,10-
phenanthroline; phospholipase C inhibitor U73122 (Figure 1C).
However, ultracentrifugation of conditioned media resulted in
the loss of T-cad from supernatants with simultaneous accumu-
lation of the protein in the pellets (Figure 1A), suggesting that the
major fraction of T-cad was released in association with MPs
rather than as soluble or cleaved protein.
T-cadherin is present on the surface
of microparticles released from
endothelial cells
To determine whether endothelial MPs harbour T-cad, MPs were
isolated from TNF-a-treated HUVEC culture supernatants and
characterized by electron microscopy (Figure 2A), immunoblotting
(Figure 2B), and flow cytometry (Figure 2C–F). Isolated MPs had
diameters of less than 1 mm (Figure 2A). The number of collected
MPs was 190+ 35/103 cells (mean+ SD of five isolations)
(Figure 2C). T-cad was present on MPs collected from culture
supernatants of parental and T-cad-overexpressing HUVEC
(Figure 2B). Flow cytometry analysis showed that MPs from par-
ental HUVEC stained positively for annexin V, a characteristic
feature of these apoptotic vesicles exposing phosphatidylserine
on their outer membrane surface,6–8 and annexin binding was
decreased in the absence of Ca2+, confirming the specificity of
the staining (Figure 2D). MPs isolated from HUVEC culture super-
natants were, as expected, double-positive for CD31 and annexin
V (53% of all MPs) (Figure 2E). With immunolabelling for T-cad and
annexin V, 67% of all the MP population were double-positive, con-
trasting with minimal double-positivity in control samples labelled
with either annexin V in the absence of Ca2+ (8%) or isotype
control IgG (14%) (Figure 2F).
Figure 1 T-cadherin (T-cad) is present in culture supernatants from endothelial cells (ECs) in vitro. (A) Immunoblotting for T-cad in 24 h
culture media collected from parental human umbilical vein endothelial cells (HUVEC) (wt), and HUVEC-overexpressing human T-cad
(T-cad+) or c-myc-tagged T-cad protein (T-cad/c-myc). Ultracentrifugation of starting media at 100 000 g and 200 000 g resulted in the loss
of T-cad from supernatants (s-100 000 and s-200 000) with simultaneous accumulation of protein in the pellets (p-100 000 and p-200 000).
(B) Immunoblotting for T-cad in media from parental HUVEC after 5 h of treatment with indicated stress-inducing agents or vehicle controls.
(C) Immunoblotting for T-cad in media from parental HUVEC after 8 h of treatment with 100 ng/mL TNF-a in the absence (control) or pres-
ence of various inhibitors of enzymes inducing protein cleavage: bisindoylmaleimide (BIM, 1026 mol/L), staurosporine (stauro, 1029 mol/L),
phorbol myristate acetate (PMA, 1026 mol/L), phenylmethylsulphonyl fluoride (PMSF, 1026 mol/L), Sigma proteolytic cocktail (prot.inhib.,
1:100), aprotinin (aprot, 1026 mol/L), EDTA (1 mmol/L), filipin (8 × 1026 mol/L), 1,10-phenanthroline (phenanth., 1023 mol/L), and U73122
(1025 mol/L).
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Endothelial microparticles expressing
T-cadherin on their surface can induce
T-cadherin-dependent signalling and
angiogenic behaviour in endothelial cells
In vitro homophilic ligation of cell surface T-cad by recombinant
T-cad protein or agonistic antibody induces intracellular signalling
and the angiogenic phenotype in ECs.16,18 How such ligation
might occur in vivo is unclear, since in intact EC monolayers
T-cad, like other GPI-anchored molecules, is present on the
apical surface of cells and not at sites of intercellular contacts.19
MPs are recognized as diffusible vectors for the transfer of biologi-
cal information from one cell to another (homotypic or heteroty-
pic) within proximal or remote tissues.7,8 To test the postulate that
T-cad-carrying MPs represent ligands inducing T-cad-dependent
signalling and behaviour in target ECs, we performed
gain-of-function experiments. MPs collected from T-cad-
overexpressing ECs (MP-T) and control vector-transduced ECs
(MP-E) were analysed for their ability to induce Akt phosphoryl-
ation in HUVEC, human aortic endothelial cells (HAECs), and
human microvascular endothelial cell line (HMEC-1). Comparable
results were obtained for all EC types. Both MP-E and MP-T
induced a quick Akt phosphorylation response in parental EC,
which was observed within 5 min after addition of MPs to cell cul-
tures, reached its peak within 10–15 min (Figure 3A, images herein
show data for HUVEC and HAEC only), and was normalized within
45 min (not shown). The response to MP-T during the first 10 min
was significantly more pronounced than that induced by MP-E
(Figure 3A). To exclude that signalling might be induced by traces
of foetal calf serum or cytokines in MP preparations, we treated
HUVEC with equal volumes of the final phosphate-buffered
saline (PBS) supernatants collected during the preparation of
Figure 2 T-cad is present on microparticles (MPs) released from apoptotic ECs. (A) Electronmicroscopic characterization of MPs isolated from
TNF-a-treated (4 mmol/L, 24 h) HUVEC. (B) Immunoblotting for T-cad in MPs isolated from TNF-a-treated parental (wt) and
T-cad-overexpressing HUVEC (T-cad+). (C–F) Flow cytometry of MPs from TNF-a-treated HUVEC. (C) MPs were defined on a dot-plot histo-
gram (region R2) and counted using an internal standard of calibrating TruCOUNT beads (R1). (D) Staining with annexin V–FITC conjugate with
the confirmation of specific annexin V binding by staining in the absence of Ca2+. (E) MPs are double-positive for annexin V and CD31. Isotype
control IgG-PE conjugate was used as negative control. (F ) MPs are double-positive for annexin V and T-cad. Negative controls: labelling with
isotype control IgG and annexin V in the absence of Ca2+. Experiments were performed on at least three separate occasions.
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MP-E and MP-T (sup-E and sup-T, respectively). No Akt phos-
phorylation was observed in response to either sup-E or sup-T
(Figure 3B).
To validate T-cad-specific effects of MP-T on Akt phosphoryl-
ation, we performed gain-of-function and loss-of-function experi-
ments using T-cad-overexpressing and T-cad-silenced HMEC-1.
Firstly, we examined the responses of T-cad-silenced (shT) and
control shRNA-transduced (shC) HMEC-1 to MP-T and MP-E
derived from T-cad-overexpressing and control-transduced
HMEC-1, respectively. The Akt phosphorylation response of
shC-HMEC-1 to MP-T was greater than that to MP-E (Figure 3C).
In contrast, for shT-HMEC-1, the Akt phosphorylation responses
to MP-E and MP-T were comparable (Figure 3C). Secondly, we
examined the response of parental HMEC-1 to MPs collected
from shT-HMEC-1 or shC-HMEC-1. MPs from T-cad-silenced
HMEC-1 induced a markedly weaker and delayed response than
Figure 3 Endothelial MPs carrying T-cad induce T-cad-dependent Akt phosphorylation in ECs. (A) MPs from control-transduced (MP-E) and
T-cad-overexpressing (MP-T) cultures of HUVEC, human aortic endothelial cells (HAEC), or human microvascular endothelial cell line
(HMEC-1) were added (10 mg/mL) or not (control) to the corresponding parental cultures (data for HMEC-1 not shown). (B) As negative
controls, parental HUVECs were treated with equal volumes of the final PBS supernatants collected during the preparation of MP-E and
MP-T (sup-E and sup-T, respectively). (C) T-cad-silenced (shT) or control vector-transduced (shC) HMEC-1 treated with HMEC-1-derived
MP-E or MP-T. (D) Parental HMEC-1 treated with MP collected from shT or shC HMEC-1. (A–D) Whole cell lysates prepared at the indicated
times (minutes) were immunoblotted for phospho-Akt or GAPDH as internal loading control. Total Akt levels in ECs were not altered by
MP-E, MP-T, sup-E, or sup-T (data not shown). Representative blots are shown and data in histograms are given as mean+ SEM (n ¼ at
least 3). Two-way (A, B, D) and three-way (C) ANOVA; *P, 0.05; **P, 0.01; ***P, 0.001; §P, 0.001.
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MP from shC-HMEC-1 (Figure 3D). These data support that acti-
vation of intracellular signalling in target EC by MP-T depended
upon T-cad homophilic interactions.
Next, we investigated whether effects of T-cad-carrying MP on
intracellular signalling might translate into relevant biological
effects. Angiogenic behaviour of EC was selected as the functional
read-out since in vitro and in vivo studies have identified T-cad as a
proangiogenic molecule.16,18 Moreover, an important action of MP
in the vascular system is their ability to induce angiogenesis.7,8,20
MP-E and MP-T were added to HMEC-1 monolayers and their
effects on angiogenic behaviour were monitored by time-lapse
videomicroscopy. In parental HMEC-1, both types of MP induced
a proangiogenic phenotype and formation of net structures, but
for MP-T the total length of tubular structures was greater
(Figure 4A), and onset of network formation occurred earlier
(Figure 4B). The angiogenic response of T-cad-silenced HMEC-1
(shT) to MP-T was significantly lower than that of control
HMEC-1 (shC) (Figure 4C). These data demonstrate that
MP-harboured T-cad can elicit a biologically relevant and
T-cad-dependent (i.e. angiogenic) response, and further confirm
homophilic interaction of MP-T with T-cad molecules expressed
on the surface of target cells.
Figure 4 Endothelial MPs expressing T-cad on their surface facilitate angiogenesis in vitro. MP-E or MP-T were added (10 mg/mL) to parental
HMEC-1 monolayers (A, B), T-cad-silenced (shT), and control-transduced (shC) HMEC-1 (C). Formation of tubular structures was monitored
by time-lapse videomicroscopy over 36 h. Morphometric analysis of the length of tubular structures (A, C) was performed on either videomicro-
scopy still-frames or after fixation/staining of cells. Images depict fixed/stained cells (A, 36 h) and still-frames after 0, 24, and 36 h (B) or 24 h (C).
Scale bars ¼ 0.1 mm (A, B) or 0.2 mm (C). Data in histograms (mean+ SEM, n ¼ 3) present morphometric analysis at 24 h. One-way (A) and
two-way (C) ANOVA; **P, 0.01.
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T-cadherin is present in human plasma at
increased levels during early stages of
atherosclerosis and correlates with
endothelial dysfunction
We next addressed whether T-cad might be present in the plasma
of human donors and whether plasma levels of T-cad reflect in vivo
ED and/or injury. The clinical characteristics of the study popu-
lations are shown in Table 1; there was a population of young
healthy volunteers, a population of middle-aged patients with inter-
mediate atherosclerotic risk and non-significant atherosclerosis,
and a slightly older population with highly prevalent cardiovascular
risk factors and documented chronic CAD.
ELISA of plasma samples demonstrated the presence of T-cad in
13.3% of healthy volunteers, in 42.9% of patients with non-
significant atherosclerosis, and in 34.6% of patients with chronic
CAD (Figure 5A). Levels of T-cad in both patient groups were sig-
nificantly higher than healthy volunteers (Figure 5A and B), even
with exclusion from the analysis of patients with outlying high
T-cad plasma levels (Figure 5B). Levels of T-cad between the
patient groups did not differ significantly (Figure 5B).
In patients with chronic CAD or non-significant atherosclerosis,
Spearman’s correlation using continuous variables revealed a sig-
nificant (P ¼ 0.043) dependency of T-cad and degree of ED as
measured by RH-PAT (Figure 5C). Patients with elevated T-cad
had a lower RH-PAT index (rho ¼ 20.187), further suggesting a
link between ED and T-cad release into the circulation. To
further evaluate the relationship between T-cad and RH-PAT, we
divided the RH-PAT scores into three categories1–4 and the sub-
jects into T-cad producers or non-producers, and performed a
x2-test of independence on the counts. The Fisher’s exact test
showed a P-value of 0.046.
In multivariate logistic regression adjusted for age, gender, cardi-
ovascular risk factors (smoking, diabetes, hypertension, hyperlipi-
daemia, and family history), and statin use, only a lower RH-PAT
index was significantly associated with elevated T-cad (OR 2.2
for elevated T-cad in patients with lower vs. higher RH-PAT;
Table 2).
Microparticles isolated from plasma
express T-cadherin on their surface
To analyse whether T-cad is released into the circulation on the
surface of endothelial MP, we isolated and characterized MP
from the plasma of human donors. Analysis was performed on
several plasma samples (n ¼ 7) identified as positive for T-cad
protein in ELISA. Figure 6 shows representative stainings of
samples from patients with non-significant atherosclerosis. Triple
staining for endothelial protein CD31/PECAM-1, T-cad, and
annexin V demonstrated that 40% of isolated MP (953+
112 events/ml, average from three measurements) were CD31+
and annexin V+, thus representing endothelial apoptotic MP. Of
these, 18% were also T-cad+ (Figure 6A, upper panels; lower
panels show negative control stainings). Since CD31 is also
present on platelets and leucocytes, we validated the EC origin
of T-cad+-MP using EC-specific marker, CD144/VE-cadherin.
Twenty-five percent of CD144+-MP (total number 242+
70 events/ml) were T-cad+ (Figure 6B, right upper panel; lower
panel shows negative control staining). To illustrate that levels of
T-cad determined by ELISA reflect the level of EC-derived
MP-bound T-cad in plasma, we compared the analysis presented
in Figure 6B with a parallel analysis of plasma samples from patients
and healthy controls containing negligible T-cad on ELISA; these
samples exhibited very low levels of CD144+/T-cad+-MP (Sup-
plementary material online, Figure S1). Staining for other cell-type
markers (Figure 6C) showed the presence of MP originating from
platelets (602+ 142 events/ml positive for CD41/GpIIb), erythro-
cytes (141+33 events/ml positive for CD235a/glycophorin A),
and leucocytes (94+ 29 events/ml positive for CD45). Negligible
levels of double-positivity were detected in samples co-stained
for T-cad and any of these markers (Figure 6C, upper panels;
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Age (years) 27.3+3.1 55.9+9.9 62.3+9.3 ,0.001
Gender 20 females/10 males 29 females/34 males 40 females/122 males 0.002
Risk factors
Smoking 0/30 (0.0%) 24/63 (38.1%) 94/162 (58.0%) 0.007
Diabetes 0/30 (0.0%) 6/63 (9.5%) 35/162 (21.6%) 0.035
Hypertension 0/30 (0.0%) 30/63 (47.6%) 103/162 (63.6%) 0.029
Hyperlipidaemia 0/30 (0.0%) 25/63 (39.7%) 116/162 (71.6%) ,0.001
Family history 0/30 (0.0%) 23/63 (36.5%) 58/162 (35.8%) 0.921
Medications
Beta-blockers 0/30 (0.0%) 28/63 (44.4%) 104/162 (64.2%) 0.007
ACE-inhibitors 0/30 (0.0%) 17/63 (27.0%) 81/162 (50.0%) 0.002
Ca2+ antagonists 0/30 (0.0%) 5/63 (7.9%) 36/162 (22.2%) 0.013
Statins 0/30 (0.0%) 25/63 (39.7%) 143/162 (88.3%) ,0.001
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negative control labelling is shown in lower panels), supporting the
EC origin of T-cad harbouring MPs in plasma.
Discussion
We have previously demonstrated that T-cad protein expression
on EC is upregulated under conditions leading to EC activation
and damage.13,14 Here, we provide evidence that T-cad can be
shed from EC and in amounts reflecting the extent of activation
or damage. Firstly, in vitro studies demonstrated that T-cad
protein is present on MP released from stressed/apoptotic EC,
and that these MP can induce T-cad-dependent signalling and a
proangiogenic functional response in target cells. Secondly,
release of T-cad from EC occurs in vivo in association with ED;
Figure 5 T-cad in the plasma of human donors is increased at early stages of atherosclerosis: T-cad levels in the plasma of healthy subjects
(n ¼ 30), patients with non-significant atherosclerosis (n ¼ 63), patients with chronic CAD (n ¼ 162) was measured by sandwich ELISA. (A)
Error bars in the scatter plot are mean+ SEM. (B) T-cad levels are given as mean+ SEM. P-values indicate significance of difference
between subject groups as determined with two-sample Wilcoxon rank-sum (Mann–Whitney) test; comparison with healthy volunteersa, com-
parison between the patient groups either withoutb or withc exclusion of patients with outlying high plasma T-cad levels. (C) The correlation
between plasma T-cad levels and the degree of ED in the patients (n ¼ 225) as measured by RH-PAT was estimated with the Spearman’s
method using continuous variables (r ¼ 20.19, P, 0.05) and is depicted using linear regression with 95% confidence bands (interrupted lines).
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negligible T-cad protein was detected in the plasma of healthy
human donors, but its level was increased in the plasma from
patients with non-significant atherosclerosis and patients with
chronic CAD.
Cell surface molecules can be released into the circulation by
several mechanisms. Proteolytic cleavage of the extracellular
domains of transmembrane polypeptides by matrix metallopro-
teases, serine proteases, and disintegrins, known as ectodomain
shedding, has been demonstrated for growth factor receptors,
proteoglycans, and adhesion molecules.21 Lipid-anchored mol-
ecules, such as GPI-proteins or gangliosides can be cleaved from
the plasma membrane by phospholipases.22 In addition to being
a mechanism of regulating surface protein expression, enzymatic
cleavage is involved in the control of various cell functions since
soluble protein fragments can retain their biological activity and
act as ligands inducing signalling events in neighbouring cells.6–8
Shedding of endothelial adhesion molecules modulates adhesive
properties of luminal ECs and recruitment of inflammatory cells
to the vessel wall, thus modulating inflammatory responses.23 Clea-
vage of extracellular domains of N- and E-cadherin modulates cell
adhesive and migratory behaviour.24 Our in vitro data obtained
using inhibitors of shedding-inducing enzymes and ultracentrifuga-
tion argues for T-cad release from EC not as soluble protein,
but rather in association with some kind of cellular particles.
Flow cytometry confirmed the presence of T-cad on the surface
of endothelial apoptotic MP (or ectosomes), both in conditioned
culture medium and in the plasma of human donors in vivo. Not-
withstanding, proteolysis or lipolysis as alternative mechanisms
for shedding surface T-cad cannot be completely excluded, since
trace amounts of T-cad were occasionally detected in medium
clarified by ultracentrifugation.
In addition to their characteristic loss of plasma membrane
asymmetry and exposure of phosphatidylserine (annexin V positiv-
ity) on the outer leaflet, MPs harbour membrane and cytoplasmic
components of the cell of origin.6–8 Our flow cytometry analysis
of MPs from human plasma showed that MPs of platelet,
erythrocyte, or leucocyte origin were negative for T-cad. EC
origin of T-cad-containing MPs was demonstrated by their positiv-
ity for EC-specific marker CD144/VE-cadherin. Exosomes are
another type of cell-derived microvesicles found in extracellular
medium in vitro and in the circulation. They are smaller than MPs
and more homogenous in size (approximately 50–90 nm), orig-
inate from intracellular multivesicular bodies, are released from
the cell via exocytic fusion with the plasma membrane, and are dis-
tinct from MPs in membrane composition and function.25 Since
exosomes will pellet together with MPs during centifugation at
100 000 g, it should be considered that microvesicular-associated
T-cad is not restricted to MPs and might also be present on exo-
somes. We did not specifically address this issue. Nevertheless,
exosomes are too small for easy detection by flow cytometry
and usually require immunocoupling to carrier beads.25 Our flow
cytometry analysis shows that microvesicles corresponding in
size to MPs and carrying endothelial plasma membrane markers
are positive for T-cad, permitting us to conclude that a significant
pool of microvesicles carrying T-cad represent MPs.
The precise mechanisms leading to increased elevation of
MP-bound T-cad in the plasma of patients with non-significant ather-
osclerosis and patients with chronic CAD are unclear. T-cad is upre-
gulated on ECs early upon activation and stress in vitro,13–15 is
elevated on ECs during atherosclerosis,11 and can undergo redistri-
bution within the plasma membrane of activated vascular cells.19
Therefore, local conditions of EC activation owing to endothelial
shear stress together with the presence of proatherogenic inflam-
matory, thrombotic, apoptotic, or oxidative substances,26,27 and a
possible concomitant upregulation of T-cad gene expression or
even redistribution of protein within the plasma membrane
are factors that might underlie increased membrane vesiculation
and/or increased levels of T-cad in blebbing plasma membrane
domains.
There is considerable interest in plasma biomarkers that provide
information about the functional status of the cardiovascular
system at early stages of atherogenesis before acute clinical mani-
festations take place. Since recent IVUS studies demonstrate high
incidence of coronary atherosclerotic lesions even in asympto-
matic teenagers and young adults,28 of special importance would
be markers that help to detect not only intimal thickening but
the shift from silent to acute disease that manifests itself in func-
tional abnormalities. Promising candidates include markers of
acute or chronic inflammatory processes occurring in the coronary
vessel wall during atherogenesis, such as soluble forms of endo-
thelial adhesion molecules, or C-reactive protein for which even
a small elevation was shown to be a powerful independent predic-
tor of future vascular events in apparently healthy asymptomatic
individuals.4,29 Accumulating evidence supports a prognostic role
of ED in CAD;1,3 however, only von Willebrand factor and
E-selectin are viewed as biochemical markers specifically reflecting
ED. Since our patient subgrouping was based on angiographic and
IVUS parameters, an elevation in plasma T-cad cannot be unequi-
vocally interpreted as a criterion for distinguishing between indo-
lent and functionally relevant disease. Nevertheless, ED
represents one the earliest functional disturbances that precede
acute coronary events. We found both the presence of T-cad
plasma in patients with non-significant atherosclerosis and an
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Multivariate logistic regression
OR (95%CI) P-value
Age (OR per year increase) 1.00 (0.97–1.03) 0.782
Gender (OR for female vs. male) 1.61 (0.84–3.10) 0.155
Smoker (OR for smoker vs.
non-smoker)
1.33 (0.73–2.44) 0.356
Diabetes (OR for diabetes vs. no
diabetes)
0.92 (0.43–1.99) 0.840







Family history (OR for family history vs.
no family history)
1.04 (0.57–1.88) 0.907
Statin use (OR for statin vs. no statin) 1.00 (0.49–2.05) 0.998
RH-PAT index (OR for low vs. high) 2.19 (1.16–4.16) 0.016
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association between T-cad levels and degree of ED. Therefore, it is
plausible to consider T-cad as a marker of early-stage athero-
sclerosis, which is clinically silent but characterized by disturbances
in endothelial function.
Interestingly, although ELISA clearly demonstrated elevation of
T-cad in plasma in patients with atherosclerosis when compared
with healthy subjects, T-cad levels between patients with chronic
CAD and those with non-significant atherosclerosis (albeit slightly
higher) were not significantly different. This might be explained by
the assumption that T-cad levels reflect not so much the actual
vessel occlusion but rather the state of endothelial activation and
dysfunction. Our previous in vitro studies on oxidative stress14
and endoplasmic reticulum stress30 show that T-cad expression
on EC is upregulated within 2–3 h of treatment with pro-
inflammatory and pro-apoptotic agents and thereafter declines
when manifestations of acute cell damage and death become
obvious. Here, T-cad upregulation represents a protective mech-
anism that can shift the balance in cellular stress response to the
prosurvival signalling branches, which is only later followed by
alarm and apoptotic phases. In vivo, this phenomenon might
Figure 6 Flow cytometry characterization of T-cad-harbouring MPs in human plasma. (A) Representative dot-plot graphs show triple staining
of MP preparations for CD31, T-cad, and annexin V (upper panels) or triple staining with matching isotype control IgG conjugates and annexin
V labelling in the absence of Ca2+ performed for negative controls (lower panels). (B) Double stainings of MP for T-cad and VE-cadherin (upper
panel) or respective isotype controls (low panels). (C) Double stainings of MP for T-cad, GpIIb, GFA, or CD-45 (upper panels, left to right) and
double staining with matching isotype control IgG conjugates (lower panels).
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translate into an attempt of vascular cells to limit tissue dysfunction
and damage at the onset of atherosclerosis.
Many studies have demonstrated that MP shedding is a hallmark
of endothelial activation and injury. Circulating MP levels correlate
with the degree of ED, impaired vasodilatation in patients with
chronic and end-stage renal failure, and acute coronary syndromes,
and are increased in patients with hypercholesterolaemia, hyper-
tension, and diabetes.5–7 Two recent papers present evidence
for potential usefulness of endothelial MP levels in the identifi-
cation of patients at immediate risk of acute cardiovascular
events. Assessment of endothelial dysfunction by measurement
of endothelial MP independently predicted cardiovascular events
in patients with coronary heart disease suggesting this readout as
an important component of a multiple biomarker strategy of
improving risk stratification.31 Bernard et al. showed an association
between CD144+-MP and the presence of coronary non-calcified
vulnerable plaques indicating that elevation of endothelial MP may
predict acute thrombotic events in type 2 diabetic patients.32
Identification of T-cad as an endothelial MP antigen in vivo has
potential value with respect to the detection of endothelial acti-
vation/injury. However, it must be recognized that considerable
technical difficulties are associated with standardized isolation,
measurement, and characterization of MP, and utilization of MP
as a reproducibly quantifiable parameter is far from the main-
stream clinical analysis. Although cell-free T-cad is mostly
MP-bound, we successfully applied ELISA-based methodology to
measure T-cad in human plasma. This methodology offers a
more reliable and simple technical opportunity to detect ED
characterized by the elevation of ‘biomarker’ endothelial MP in
plasma.
A limitation of the study is that healthy subjects in the control
group were significantly younger than patients in both groups with
atherosclerosis. However, it seems unlikely that age is a potential
confounder that results in elevated plasma T-cad in our patient
groups. In our multivariate logistic regression analysis, age does
not show up as a factor (OR 1.0). This is important since the
other variables are age-prone factors. On the other hand, a lower
RH-PAT index (ED) shows up with an OR 2.2 (P, 0.016), which
underscores that the level of T-cad in plasma is a factor that
relates to endothelial activation/dysfunction, and, irrespective of
age, may reflect a prevailing state of vascular activation and injury.
Relevance for an association between T-cad in plasma and ED is
underscored by the recent genome-wide association studies aimed
at identification of genetic variants contributing to cardiovascular
disease. The Framingham Heart Study33 and Org et al.34 demon-
strated correlations between single nucleotide polymorphisms
within intron 11 and promoter regions of CDH13 gene and long-
term average diastolic and systolic blood pressure phenotypes and
arterial stiffness, indicating a role for T-cad in progression of hyper-
tension. The impact of T-cad within the complicated network of
processes contributing to cardiovascular disorders is seemingly
broad. T-cad has been identified as a receptor for adipose tissue-
derived adiponectin,35 a hormone that profoundly affects pro-
gression of atherosclerosis and diabetes by modulating insulin sen-
sitivity, lipoprotein metabolism, and EC function. T-cad also acts as
a receptor for low-density lipoproteins,36 suggesting a role in the
regulation of EC function in hypercholesterolaemia.
Our study has also revealed a novel mechanism of
T-cad-dependent signalling in the vasculature. Like other members
of the cadherin superfamily, T-cad is capable of homophilic–
ligation interactions mediating intercellular adhesion and inducing
intracellular signalling events. Downstream signalling pathways
seem to be activated by both T-cad ligation and upregula-
tion.13,14,16,18 Ligation of T-cad on the cell surface is equivalent in
vivo to trans-interactions between T-cad molecules on neighbour-
ing cells and can be mimicked in vitro by the addition of recombi-
nant T-cad protein or agonistic antibody to T-cad-expressing
cells. In the case of T-cad overexpression, downstream signalling
might be induced either by cis-clustering of T-cad molecules
within the plasma membrane or by increased engagement of
T-cad-signalling adaptor molecules. In the intact endothelial mono-
layer, T-cad is expressed only on the apical surface and not in the
intercellular contacts.19 Such a cellular localization pattern in vivo
(i.e. facing the vessel lumen) restricts opportunities for T-cad
ligation-induced signalling. By demonstrating that T-cad-harboured
MP can induce Akt phosphorylation and the proangiogenic pheno-
type in target EC, we have identified MP as a novel physiological
ligand capable of initiating T-cad-dependent signal transduction in
the endothelium. These T-cad-mediated homophilic-based inter-
actions may occur both in a paracrine or in an autocrine
manner, i.e. induce signalling in distant ECs or ECs from which
MPs were released.
Depending on the origin and protein composition, the outcome
of MP binding to endothelial and blood cells might be adverse (e.g.
promotion of thrombotic events) or beneficial (e.g. tissue regener-
ation).7,8 In vivo, the interaction of plasma-delivered T-cad-
harbouring MP to the luminal endothelium, accompanied by an
upregulation of surface T-cad expression on activated/injured EC,
might function to regulate patho(physiological) processes involving
endothelial activation and stress, and therefore influence vessel
remodelling.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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